Skip to content

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01723059
Enrollment
184
Registered
2012-11-07
Start date
2012-02-29
Completion date
2013-01-31
Last updated
2012-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Infection

Brief summary

Traditionally, H pylori infection has been treated with conventional triple therapy. This includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days. In Europe, the guidelines now advocate treatment of H pylori with sequential therapy which is 5 days of amoxicillin therapy with proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and proton pump inhibitor with better response rates. We hypothesize that H. pylori resistance pattern and treatment response rates observed in Europe will not be predictive of resistance patterns and response rates in the United States.

Interventions

total 10 days

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.
CollaboratorINDUSTRY
Dallas VA Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Subject has signed informed consent Subject is an adult older than 18 yrs old and requires an upper endoscopic evaluation If female and of child bearing potential, subject has a negative pregnancy test and is not nursing. Patient has not received prior treatment for H pylori Subject is able to understand and comply with study procedures

Exclusion criteria

Recent use (within 4 weeks) of any of the medications used in the treatment of H pylori(Amoxicillin, Clarithromycin, Metronidazole) Subject undergoing endoscopy for acute gastrointestinal bleeding Subject has an allergy to any of the medications used in the treatment of H pylori Subject has a history of esophageal or gastric carcinoma including lymphoma Subject has esophageal varices or undergoing endoscopy for esophageal banding Subject is taking warfarin or clopidogrel Subject has coagulopathy that precludes safe biopsy of the biopsy areas Subject has comorbidity that precludes safe participation in the study Subject is a pregnant female Subject has a history of H. pylori infection. Patient is already enrolled in GI Study. History of UGI surgery other than Nissen Fundoplication

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori eradication4 weeks after completion of treatment

Countries

United States

Contacts

Primary ContactByron Cryer, MD
byron.cryer@utsouthwestern.edu214-857-1603
Backup ContactElizabeth Coss, MD
elizabeth.coss@phhs.org817-896-7030

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026